Robert Driscoll
Stock Analyst at Wedbush
(3.33)
# 849
Out of 4,654 analysts
152
Total ratings
39.57%
Success rate
5.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $15.39 | +81.94% | 8 | Oct 25, 2024 | |
| BDTX Black Diamond Therapeutics | Reiterates: Outperform | $16 | $2.62 | +510.69% | 10 | Oct 8, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Outperform | $30 | $15.70 | +91.08% | 7 | Oct 3, 2024 | |
| IGMS IGM Biosciences | Maintains: Outperform | $25 → $22 | $9.47 | +132.31% | 10 | Oct 1, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $54 → $52 | $26.64 | +95.20% | 8 | Sep 24, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $85 → $51 | $16.61 | +207.04% | 1 | Sep 20, 2024 | |
| ACET Adicet Bio | Reiterates: Outperform | $5 | $0.95 | +428.04% | 8 | Sep 20, 2024 | |
| CGEM Cullinan Therapeutics | Reiterates: Outperform | $36 | $13.86 | +159.74% | 4 | Sep 18, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Outperform | $11 | $7.74 | +42.12% | 3 | Sep 12, 2024 | |
| APRE Aprea Therapeutics | Reiterates: Outperform | $11 | $3.25 | +238.46% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $4 | $3.47 | +15.27% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $37 | $15.92 | +132.41% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $8.01 | +62.30% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $3.85 | +237.66% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $48.76 | +51.76% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $59 | $55.13 | +7.02% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $0.83 | +1,348.58% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.38 | +479.71% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $22.48 | +153.56% | 8 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $3.66 | +91.26% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $0.91 | +779.12% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $0.53 | +1,405.17% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $10.80 | +381.48% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $13.31 | +162.96% | 5 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $1.77 | +408.47% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.64 | +9.89% | 4 | May 19, 2020 |
Tyra Biosciences
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $15.39
Upside: +81.94%
Black Diamond Therapeutics
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.62
Upside: +510.69%
Arcus Biosciences
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $15.70
Upside: +91.08%
IGM Biosciences
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $9.47
Upside: +132.31%
IDEAYA Biosciences
Sep 24, 2024
Maintains: Outperform
Price Target: $54 → $52
Current: $26.64
Upside: +95.20%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $16.61
Upside: +207.04%
Adicet Bio
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.95
Upside: +428.04%
Cullinan Therapeutics
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $13.86
Upside: +159.74%
Monte Rosa Therapeutics
Sep 12, 2024
Reiterates: Outperform
Price Target: $11
Current: $7.74
Upside: +42.12%
Aprea Therapeutics
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.25
Upside: +238.46%
Aug 12, 2024
Upgrades: Neutral
Price Target: $4
Current: $3.47
Upside: +15.27%
Aug 9, 2024
Reiterates: Outperform
Price Target: $37
Current: $15.92
Upside: +132.41%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $8.01
Upside: +62.30%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $3.85
Upside: +237.66%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $48.76
Upside: +51.76%
Aug 8, 2024
Reiterates: Outperform
Price Target: $59
Current: $55.13
Upside: +7.02%
Aug 7, 2024
Reiterates: Outperform
Price Target: $12
Current: $0.83
Upside: +1,348.58%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.38
Upside: +479.71%
Jul 31, 2024
Reiterates: Outperform
Price Target: $57
Current: $22.48
Upside: +153.56%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $3.66
Upside: +91.26%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $0.91
Upside: +779.12%
May 3, 2024
Reiterates: Outperform
Price Target: $8
Current: $0.53
Upside: +1,405.17%
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $10.80
Upside: +381.48%
Nov 7, 2023
Maintains: Outperform
Price Target: $39 → $35
Current: $13.31
Upside: +162.96%
Aug 24, 2023
Initiates: Outperform
Price Target: $9
Current: $1.77
Upside: +408.47%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.64
Upside: +9.89%